Table 3 Breast Cancer University Hospitals (UH) population (2005–2022) description and comparison stratified by race in treatment adverse events, including chemotherapy complications, irAEs (immune-related adverse events), psychological affections, and cognitive decline/dementia. IQR interquartile range; MI myocardial infarction; AKI acute kidney injury.
From: Racial disparities in breast cancer treatment patterns and treatment related adverse events
|  | Breast cancer UH population (n = 17,454) | ||
|---|---|---|---|
Black | White | p value | |
Chemotherapy complications—n (%) | 227 (20.9%) | 431 (12.2%) |  < 0.001 |
Adverse reaction—n (%) | 11 (1%) | 21 (0.6%) | 0.21 |
Cardiomyopathy—n (%) | 14 (1.3%) | 16 (0.5%) | 0.005 |
Diarrhea/enteritis—n (%) | 41 (3.8%) | 64 (1.8%) |  < 0.001 |
Fatigue—n (%) | 54 (5%) | 80 (2.3%) |  < 0.001 |
Nausea/vomiting—n (%) | 62 (5.7%) | 94 (2.7%) |  < 0.001 |
Steatohepatitis—n (%) | 6 (0.6%) | 19 (0.5%) | 1 |
Neuropathy—n (%) | 27 (2.5%) | 37 (1%) |  < 0.001 |
Thrombocytopenia—n (%) | 2 (0.2%) | 6 (0.2%) | 1 |
Lung disease—n (%) | 35 (3.2%) | 27 (0.8%) |  < 0.001 |
Pain—n (%) | 53 (4.9%) | 54 (1.5%) |  < 0.001 |
Anemia—n (%) | 10 (0.9%) | 15 (0.4%) | 0.08 |
Agranulocytosis—n (%) | 46 (4.2%) | 156 (4.4%) | 0.86 |
Mouth sore—n (%) | 0 | 2 (0.1%) | 1 |
Dehydration/hypovolemia—n (%) | 38 (3.5%) | 57 (1.6%) |  < 0.001 |
Renal failure—n (%) | 1 (0.1%) | 0 | 0.53 |
Rash—n (%) | 7 (0.6%) | 1 |  < 0.001 |
Infusion reaction—n (%) | 6 (0.6%) | 5 (0.1%) | 0.03 |
IRAES—n (%) | 47 (36.4%) | 153 (37.7%) | 0.06 |
Anemia—n (%) | 10 (7.8%) | 36 (8.9%) | 0.83 |
Thrombocytopenia—n (%) | 2 (1.6%) | 20 (4.9%) | 0.15 |
Leukopenia—n (%) | 9 (7%) | 45 (11.1%) | 0.23 |
Hypothyroidism—n (%) | 11 (8.5%) | 43 (10.6%) | 0.60 |
Hyperthyroidism—n (%) | 2 (1.6%) | 4 (1%) | 0.95 |
Hypophysitis/PGA—n (%) | 3 (2.3%) | 5 (1.2%) | 0.63 |
Hyper/hypo- parathyroidism—n (%) | 0 | 4 (1%) | 0.58 |
AKI—n (%) | 8 (6.2%) | 14 (3.4%) | 0.26 |
Neuritis—n (%) | 4 (3.1%) | 11 (2.7%) | 1 |
Hepatitis—n (%) | 0 | 3 (0.7%) | 0.76 |
Colitis—n (%) | 3 (2.3%) | 16 (3.9%) | 0.55 |
Pancreatitis—n (%) | 3 (2.3%) | 1 (0.2%) | 0.07 |
Mucositis—n (%) | 1 (0.8%) | 3 (0.7%) | 1 |
Arrhythmia—n (%) | 7 (5.4%) | 28 (6.9%) | 0.70 |
Acute MI—n (%) | 4 (3.1%) | 1 (0.2%) | 0.01 |
Myocarditis—n (%) | 7 (5.4%) | 24 (5.9%) | 1 |
Pericarditis—n (%) | 0 | 2 (0.5%) | 1 |
Cardiomyopathy—n (%) | 3 (2.3%) | 9 (2.2%) | 1 |
Pneumonitis—n (%) | 10 (7.8%) | 8 (2%) | 0.003 |
Type I diabetes—n (%) | 2 (1.6%) | 3 (0.7%) | 0.75 |
Meningitis—n (%) | 0 | 0 | - |
Encephalitis, myelitis, encephalomyelitis—n (%) | 0 | 0 | - |
Vitiligo—n (%) | 1 (0.8%) | 0 | 0.54 |
Psychological affections—n (%) | 598 (26.4%) | 2,505 (27.5%) | 0.30 |
Depression—n (%) | 381 (16.8%) | 1,516 (16.6%) | 0.86 |
Anxiety—n (%) | 440 (19.4%) | 1,893 (20.8%) | 0.15 |
Bipolar Disorder—n (%) | 36 (1.6%) | 96 (1.1%) | 0.04 |
Cognitive decline/dementia—n (%) | 308 (13.6%) | 608 (6.7%) |  < 0.001 |
